Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stereotactic radiotherapy Clear all

Conditions: Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Interventions: L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy; Radiation · Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: Metastatic Malignant Solid Neoplasm
Interventions: Computed Tomography, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Positron Emission Tomography, Questionnaire Administration; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Malignant Neoplasm to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Hypofractionated Radiosurgery; Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Liver Metastases
Interventions: SBRT; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
Interventions: Indoximod, Temozolomide, Bevacizumab, Stereotactic Radiation; Drug · Radiation
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 16 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 17
States / cities: Castro Valley, California • Los Angeles, California • Orange, California + 14 more

Conditions: Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Lung Non-Small Cell Squamous Carcinoma, Minimally Invasive Lung Adenocarcinoma, Neuroendocrine Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Large Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8
Interventions: Nivolumab, Stereotactic Body Radiation Therapy; Biological · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 3
States / cities: Conroe, Texas • Houston, Texas

Conditions: Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease
Interventions: IMSA101; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
Interventions: Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy; Device · Other · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Stereotactic radiotherapy delivered by CyberKnife, stereotactic radiotherapy; Radiation
Lead sponsor: Essentia Health; Other
Eligibility: 60 Years to 60 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Oligometastatic Prostate Cancer (OMPC)
Interventions: AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 39
States / cities: Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Tumors Metastatic to Brain
Interventions: sorafenib tosylate, stereotactic radiosurgery, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cancer, Palliative Radiotherapy
Interventions: Lattice stereotactic body radiation therapy, Peripheral blood; Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Interventions: Radiation Therapy Treatment Planning and Simulation, SBRT; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Male only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 3
States / cities: Rockford, Illinois • Johnson Creek, Wisconsin • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Radiation, Radiation SBRT only, ADT; Radiation · Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 46
States / cities: Antioch, California • Dublin, California • Fremont, California + 33 more

Conditions: Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions: Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV; Radiation
Lead sponsor: Ayal A. Aizer, MD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney Cancer Metastatic, Kidney Cancer, Kidney Cancer, Stage IV
Interventions: Nivolumab/Ipilimumab, SBRT; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Dallas, Texas

Conditions: Metastatic Prostate Cancer
Interventions: STEREOTACTIC BODY RADIOTHERAPY to the prostate gland; Radiation
Lead sponsor: Sharp HealthCare; Other
Eligibility: 18 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Renal Cell Carcinoma
Interventions: CyberKnife; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Chicago, Illinois • Buffalo, New York • Milwaukee, Wisconsin

Conditions: Pancreatic Cancer, Adenocarcinoma
Interventions: Preoperative SBRT; Radiation
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glioblastoma Multiforme
Interventions: Atezolizumab + FSRT radiation; Combination Product
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Prostate Cancer, Oligometastases
Interventions: SBRT; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Thoracoabdominal Wall Pain, Secondary to Parietal Pleura or Parietal Peritoneum Disease
Interventions: Single-fraction stereotactic radiosurgery (SRS); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Lung Cancer, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Interventions: Fludeoxyglucose F-18, Positron Emission Tomography (PET), Stereotactic Body Radiation Therapy (SBRT); Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Tumors, ONE SHOT Trial

Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis

Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer

Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients

Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer

A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer

Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

Stereotactic Body Radiation for Prostate Oligometastases

A Study of Stereotactic Radiosurgery (SRS) to Treat Pain in the Chest and/or Stomach Wall

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy